Bone Biologics (NASDAQ:BBLG) Issues Quarterly Earnings Results

Bone Biologics (NASDAQ:BBLG) released its quarterly earnings data on Thursday. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.11, FiscalAI reports.

Bone Biologics Trading Down 2.3%

Shares of Bone Biologics stock traded down $0.03 on Thursday, reaching $1.27. The stock had a trading volume of 13,541 shares, compared to its average volume of 20,423. Bone Biologics has a 1 year low of $1.05 and a 1 year high of $6.75. The company has a market cap of $2.28 million, a P/E ratio of -0.34 and a beta of 0.89. The business’s 50 day moving average is $1.26 and its two-hundred day moving average is $1.50.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Bone Biologics has a consensus rating of “Sell”.

Institutional Investors Weigh In On Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC lifted its position in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the quarter. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. 34.30% of the stock is currently owned by institutional investors and hedge funds.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.